Education
About Us
Working with TipRanks
Follow Us
Carisma Therapeutics (CARM)
NASDAQ:CARM
CARM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.14 - $1.38
Previous CloseN/A
Volume72.54K
Average Volume (3M)28.75M
Market Cap
$16.51M
Enterprise Value$46.45M
Total Cash (Recent Filing)$7.74M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 07, 2025EPS Estimate
-0.09Last Dividend Ex-Date
Mar 08, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding41,788,097
10 Day Avg. Volume2,695,470
30 Day Avg. Volume28,748,750
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.03
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap2.81
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Carisma Therapeutics News
PremiumCompany Announcements
Carisma Therapeutics Announces Merger with OrthoCellix
PremiumCompany Announcements
Carisma Therapeutics Secures Nasdaq Listing Approval
PremiumCompany Announcements
Carisma Therapeutics Reports Q1 2025 Financial ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Bears Say
Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.
Options Prices
Currently, No data available
---
Ownership Overview
1.43%
Insiders
4.11% Mutual Funds
5.52% Other Institutional Investors
85.41% Public Companies and Individual Investors
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was $0.14 and its highest was $1.38 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $16.51M.
When is Carisma Therapeutics’s upcoming earnings report date?
Carisma Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 29 days.
How were Carisma Therapeutics’s earnings last quarter?
Currently, no data Available
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Undervalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,788,097 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in CARM
Carisma Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.00 (150.00% Upside)
$1.00 (150.00% Upside)
Blogger Sentiment
Bullish
CARM Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.65%
12-Months-Change
Fundamentals
Return on Equity
-362.79%
Trailing 12-Months
Asset Growth
-78.38%
Trailing 12-Months
Company Description
Carisma Therapeutics
Carisma Therapeutics (CARM) is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and other serious diseases. The company specializes in the engineering of macrophages, a type of white blood cell, to harness the power of the immune system to target and eliminate cancer cells. Carisma's proprietary technology platform aims to create a new class of cell therapies that can overcome the limitations of current cancer treatments.
Technical Analysis
Kiora Pharmaceuticals
―
Dogwood Therapeutics
―
Acurx Pharmaceuticals
―
Turnstone Biologics Corp.
―